Bristol Myers Squibb Raises 2026 Revenue Forecast as Newer Drugs Drive Q3 Growth
The Bristol Myers Squibb Q3 2026 results lift revenue guidance as newer drugs grow 12%. EPS fell on a $1.6 billion charge.
Hepatitis B Newborn Vaccine Trial Halted: Key Facts
Hepatitis B newborn vaccine trial halted in Guinea-Bissau over approval and consent concerns. What happened, and why the birth dose still matters.
Abbott Nutrition Business Spin-Off: $8.5B Split by 2027
Abbott nutrition business spin-off planned by end-2027: $8.5B sales, Similac and Ensure, a tax-free share distribution. What is set and what is not.
India CAR-T Therapy Development: Nucelion, VeGen Bio Pact
India CAR-T therapy development gets a boost as Nucelion and VeGen Bio partner on VL-2511, an experimental dual-target myeloma therapy.
OpenEvidence AI Healthcare Valuation: $15B Reported
OpenEvidence AI healthcare valuation reportedly hits $15B after a $250M round. What is reported, what is confirmed and what it means for doctors.
Pennsylvania Measles Outbreak 2026: 1,317 Cases, 43 Counties
Pennsylvania measles outbreak 2026 reaches 1,317 cases in 43 counties, with 251 hospitalised and five deaths. What the update says and the MMR advice.
Zydus USFDA Approval Menopause Patch: CGT Exclusivity Win
Zydus USFDA approval menopause patch: a generic estradiol and levonorgestrel system with possible 180-day exclusivity. What is known and what is not.
Qfitlia Approval in India: Sanofi’s New Haemophilia Option
Qfitlia approval in India: CDSCO clears Sanofi’s fitusiran for haemophilia A and B in patients 12 and older. What it changes and what the data show.
India Cancer Drug Price Cap 2026: Hospital Profit Risk
India cancer drug price cap 2026 could cut some hospitals’ EBITDA by 1.5% to 3%, one analysis estimates. What is confirmed and what is a projection.
OpenAI Orchestra Bio Acquisition: A Bold Push Into Pharma
OpenAI Orchestra Bio acquisition brings drug-development coordination tools into Rosalind. Terms were not disclosed and no results are claimed.
Nigeria Ebola Case 2026: Abuja Confirms Imported Infection
Nigeria Ebola case 2026: Abuja confirms one imported Bundibugyo infection and is monitoring 44 contacts. One case is not proof of wider spread.